GET DAILY SIGNALSPulse Biosciences (PLSE) Delivers Q3 Update With Clinical Momentum in Focus
Key Takeaways
- Pulse Biosciences reported third-quarter 2026 revenue of $0.4 million, below the consensus estimate of roughly $0.52 million but up from $0.1 million a year earlier.
- GAAP net loss widened to $23.1 million, or $0.32 per share, versus a consensus loss of $0.29 per share and a $19.4 million loss in the prior-year quarter.
- The company completed enrollment in its NANOPULSE-AF U.S. pivotal study roughly three months ahead of schedule, a key clinical milestone for its cardiac ablation platform.
- Cash, cash equivalents, and marketable securities climbed to $189.2 million, supported by $95.8 million in net proceeds raised through at-the-market (ATM) offerings during the quarter.
- Investor focus remains on regulatory submissions and clinical data readouts rather than near-term revenue, which is still limited to a controlled commercial launch.
Why This Quarter Matters for Pulse Biosciences
Pulse Biosciences (PLSE) is a clinical-stage medical technology company developing a proprietary Nanosecond Pulsed Field Ablation (nsPFA) platform used to non-thermally ablate targeted cells while sparing surrounding tissue. Its primary focus is the treatment of atrial fibrillation (AF), a common heart rhythm disorder. Because the company is still in the pre-commercial phase for its cardiac products, quarterly financial figures matter less than clinical progress, regulatory milestones, and balance-sheet strength. The third-quarter report therefore carried outsized weight as investors looked for confirmation that the NANOPULSE-AF pivotal trial remained on track and that the company had sufficient capital to fund the path toward regulatory approval and a potential commercial launch. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Q3 Financial Snapshot
For the third quarter ended September 30, 2026, Pulse Biosciences reported total revenue of $0.4 million ($395,000), below the consensus estimate of roughly $0.52 million but up from $86,000 in the year-ago quarter. The revenue reflects continued case volume within the controlled launch of its Vybrance dermatology system.
The company posted a GAAP net loss of $23.1 million, or $0.32 per share, wider than the $0.29 per share consensus loss and the $19.4 million net loss reported a year earlier. Non-GAAP net loss, which excludes certain non-cash and non-recurring items, was $17.5 million, up from $13.5 million in the prior-year period, reflecting higher clinical program investment and employee-related costs.
Cash, cash equivalents, and marketable securities ended the quarter at $189.2 million, up from $101.6 million as of June 30, 2026. The company raised $95.8 million in net proceeds through its at-the-market (ATM) equity programs during the quarter, with roughly $64 million of ATM capacity remaining.
How Investors Are Reading the Results
Heading into the report, sentiment around Pulse Biosciences was driven less by financial results and more by clinical execution. The company entered the quarter having already accelerated enrollment in its NANOPULSE-AF U.S. pivotal study, and management had signaled strong physician enthusiasm for the nPulse catheter. The completed enrollment, three months ahead of the original timeline, reinforced that narrative even as the bottom line widened.
For a pre-revenue medical device company, a modest revenue miss and a slightly wider-than-expected loss are generally viewed through the lens of clinical milestones and cash runway. The balance-sheet strengthening and on-track regulatory timelines gave investors reason to weigh the near-term loss against longer-term commercial potential, though the continued cash burn and reliance on capital markets remain key risk factors that shape sentiment. From what I see, this balance of progress and spending is typical for names at this stage.
What to Watch Next
With NANOPULSE-AF fully enrolled, management's focus now shifts to pre-commercial readiness and regulatory submissions. The company is advancing modular submissions toward a Premarket Approval (PMA) application with the U.S. Food and Drug Administration (FDA), while also working toward a CE Mark in Europe, which management anticipates in the fourth quarter of 2027.
Investors should watch several catalysts. First, final patient data from the pivotal study is expected to become available in the third quarter of 2027, blending 6-month and 12-month follow-up results that will anchor the PMA submission. Second, the company plans to submit an Investigational Device Exemption (IDE) application for a persistent atrial fibrillation study in the fourth quarter of 2026, expanding the platform into a larger patient population.
Cost trends will also matter. Total GAAP costs and expenses rose to $24.7 million from $20.5 million a year earlier as the company runs multiple trials simultaneously, and management expects spending to increase further as it builds manufacturing capacity and approaches launch readiness. Meanwhile, the NANOCLAMP-AF surgical study remains on track to complete enrollment by the end of the first half of 2027.
Finally, capital deployment remains a central variable. The company ended the quarter with $189.2 million in cash and marketable securities, providing runway for ongoing trials and prelaunch investment, but continued clinical and commercialization spending will determine whether additional financing is needed before revenue scales. I’m watching this closely as the data readouts approach.
My Take on Using AI Tools for Research
In my own work following clinical-stage names like Pulse Biosciences, I find Tickeron’s AI Screener helpful for quickly scanning comparable companies and spotting shifts in technical or fundamental trends. It lets me apply filters for industry, market cap, and performance metrics in one place, which saves time when evaluating where a stock like PLSE fits among peers. This kind of structured view complements the usual review of trial timelines and cash positions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PLSE in upward trend: 10-day moving average moved above 50-day moving average on October 29, 2026
The 10-day moving average for PLSE crossed bullishly above the 50-day moving average on October 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 18 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on PLSE as a result. In 79 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.
The Moving Average Convergence Divergence (MACD) for PLSE just turned positive on October 22, 2026. Looking at past instances where PLSE's MACD turned positive, the stock continued to rise in 47 of 57 cases over the following month. The odds of a continued upward trend are 82%.
PLSE moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +4.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where PLSE advanced for three days, in 225 of 255 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
PLSE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 51 cases where PLSE's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PLSE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for PLSE entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 28 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. PLSE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 84 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: PLSE's P/B Ratio (40.901) is very high in comparison to the industry average of (5.069). P/E Ratio (-48.769) is within average values for comparable stocks, (40.009). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. PLSE's P/S Ratio (2500.000) is very high in comparison to the industry average of (56.876).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a development stage company, which manufactures surgical and medical instruments
Industry PharmaceuticalsOther
Advertisement